{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:02:55Z","timestamp":1792648975678,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-004923"],"award-info":[{"award-number":["INV-004923"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Understanding the longitudinal dynamics of antibody immunity following heterologous SAR-CoV-2 breakthrough infection will inform the development of next-generation vaccines. Here, we track SARS-CoV-2 receptor binding domain (RBD)-specific antibody responses up to six months following Omicron BA.1 breakthrough infection in six mRNA-vaccinated individuals. Cross-reactive serum neutralizing antibody and memory B cell (MBC) responses decline by two- to four-fold through the study period. Breakthrough infection elicits minimal de novo Omicron BA.1-specific B cell responses but drives affinity maturation of pre-existing cross-reactive MBCs toward BA.1, which translates into enhanced breadth of activity across other variants. Public clones dominate the neutralizing antibody response at both early and late time points following breakthough infection, and their escape mutation profiles predict newly emergent Omicron sublineages, suggesting that convergent antibody responses continue to shape SARS-CoV-2 evolution. While the study is limited by our relatively small cohort size, these results suggest that heterologous SARS-CoV-2 variant exposure drives the evolution of B cell memory, supporting the continued development of next-generation variant-based vaccines.<\/jats:p>","DOI":"10.1038\/s41467-023-38345-4","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T14:02:27Z","timestamp":1683900147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Evolution of antibody immunity following Omicron BA.1 breakthrough infection"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9854-8351","authenticated-orcid":false,"given":"Chengzi I.","family":"Kaku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6713-6904","authenticated-orcid":false,"given":"Tyler N.","family":"Starr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5740-4303","authenticated-orcid":false,"given":"Panpan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley L.","family":"Dugan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Khalif\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7306-3510","authenticated-orcid":false,"given":"Ge","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Champney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8784-8386","authenticated-orcid":false,"given":"Daniel W.","family":"Mielcarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Geoghegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6711-9864","authenticated-orcid":false,"given":"Dennis R.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8837-7520","authenticated-orcid":false,"given":"Raiees","family":"Andrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1267-3408","authenticated-orcid":false,"given":"Jesse D.","family":"Bloom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"38345_CR1","unstructured":"WHO. WHO Coronavirus (COVID-19) dashboard with vaccination data. https:\/\/covid19.who.int\/ (2023)."},{"key":"38345_CR2","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s41591-022-01753-y","volume":"28","author":"HF Tseng","year":"2022","unstructured":"Tseng, H. F. et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat. Med. 28, 1063\u20131071 (2022).","journal-title":"Nat. Med."},{"key":"38345_CR3","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S2213-2600(22)00101-1","volume":"10","author":"SY Tartof","year":"2022","unstructured":"Tartof, S. Y. et al. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study. Lancet Respir. Med. 10, 689\u2013699 (2022).","journal-title":"Lancet Respir. Med."},{"key":"38345_CR4","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41586-022-05053-w","volume":"608","author":"Q Wang","year":"2022","unstructured":"Wang, Q. et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature 608, 603\u2013608 (2022).","journal-title":"Nature"},{"key":"38345_CR5","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.cell.2022.06.005","volume":"185","author":"A Tuekprakhon","year":"2022","unstructured":"Tuekprakhon, A. et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell 185, 2422\u20132433.e13 (2022).","journal-title":"Cell"},{"key":"38345_CR6","doi-asserted-by":"publisher","unstructured":"Tamura, T. et al. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2022.12.27.521986 (2022).","DOI":"10.1101\/2022.12.27.521986"},{"key":"38345_CR7","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/j.chom.2022.09.015","volume":"30","author":"P Qu","year":"2022","unstructured":"Qu, P. et al. Evasion of neutralizing antibody responses by the SARS-CoV-2 BA.2.75 variant. Cell Host Microbe 30, 1518\u20131526.e4 (2022).","journal-title":"Cell Host Microbe"},{"key":"38345_CR8","doi-asserted-by":"publisher","unstructured":"Wang, Q. et al. Antibody response to Omicron BA.4-BA.5 bivalent booster. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMc2213907 (2023).","DOI":"10.1056\/NEJMc2213907"},{"key":"38345_CR9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1056\/NEJMc2214293","volume":"388","author":"ME Davis-Gardner","year":"2023","unstructured":"Davis-Gardner, M. E. et al. Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA bivalent booster. N. Engl. J. Med. 388, 183\u2013185 (2023).","journal-title":"N. Engl. J. Med."},{"key":"38345_CR10","unstructured":"FDA. Coronavirus (COVID-19) update: FDA authorizes Moderna, Pfizer-BioNTech bivalent COVID-19 vaccines for use as a booster dose. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use (2022)."},{"key":"38345_CR11","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","volume":"387","author":"S Chalkias","year":"2022","unstructured":"Chalkias, S. et al. A bivalent Omicron-containing booster vaccine against Covid-19. N. Engl. J. Med. 387, 1279\u20131291 (2022).","journal-title":"N. Engl. J. Med."},{"key":"38345_CR12","doi-asserted-by":"publisher","first-page":"eabq3511","DOI":"10.1126\/sciimmunol.abq3511","volume":"7","author":"CI Kaku","year":"2022","unstructured":"Kaku, C. I. et al. Recall of preexisting cross-reactive B cell memory after Omicron BA.1 breakthrough infection. Sci. Immunol. 7, eabq3511 (2022).","journal-title":"Sci. Immunol."},{"key":"38345_CR13","doi-asserted-by":"publisher","first-page":"eabq2427","DOI":"10.1126\/sciimmunol.abq2427","volume":"7","author":"J Quandt","year":"2022","unstructured":"Quandt, J. et al. Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes. Sci. Immunol. 7, eabq2427 (2022).","journal-title":"Sci. Immunol."},{"key":"38345_CR14","doi-asserted-by":"crossref","unstructured":"Wang, Z. et al. Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humans. J. Exp. Med. 219, e20221006 (2022).","DOI":"10.1084\/jem.20221006"},{"key":"38345_CR15","first-page":"521","volume":"614","author":"Y Cao","year":"2023","unstructured":"Cao, Y. et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature 614, 521\u2013529 (2023).","journal-title":"Nature"},{"key":"38345_CR16","doi-asserted-by":"publisher","first-page":"112443","DOI":"10.1016\/j.celrep.2023.112443","volume":"42","author":"P Qu","year":"2023","unstructured":"Qu, P. et al. Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants. Cell Rep. 42, 112443 (2023).","journal-title":"Cell Rep"},{"key":"38345_CR17","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s41591-022-02162-x","volume":"29","author":"C Kurhade","year":"2023","unstructured":"Kurhade, C. et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat. Med. 29, 344\u2013347 (2023).","journal-title":"Nat. Med."},{"key":"38345_CR18","doi-asserted-by":"crossref","unstructured":"Sakharkar, M. et al. Prolonged evolution of the human B cell response to SARS-CoV-2 infection. Sci. Immunol. 6, eabg6916 (2021).","DOI":"10.1126\/sciimmunol.abg6916"},{"key":"38345_CR19","doi-asserted-by":"publisher","first-page":"abm0829","DOI":"10.1126\/science.abm0829","volume":"374","author":"RR Goel","year":"2021","unstructured":"Goel, R. R. et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 374, abm0829 (2021).","journal-title":"Science"},{"key":"38345_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cell.2020.11.029","volume":"184","author":"LB Rodda","year":"2021","unstructured":"Rodda, L. B. et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. Cell 184, 169\u2013183.e17 (2021).","journal-title":"Cell"},{"key":"38345_CR21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41586-022-04778-y","volume":"607","author":"F Muecksch","year":"2022","unstructured":"Muecksch, F. et al. Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature 607, 128\u2013134 (2022).","journal-title":"Nature"},{"key":"38345_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24435-8","volume":"12","author":"AJ Greaney","year":"2021","unstructured":"Greaney, A. J. et al. Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. Nat. Commun. 12, 4196 (2021).","journal-title":"Nat. Commun."},{"key":"38345_CR23","doi-asserted-by":"publisher","first-page":"e1010951","DOI":"10.1371\/journal.ppat.1010951","volume":"18","author":"TN Starr","year":"2022","unstructured":"Starr, T. N. et al. Deep mutational scans for ACE2 binding, RBD expression, and antibody escape in the SARS-CoV-2 Omicron BA.1 and BA.2 receptor-binding domains. PLoS Pathog. 18, e1010951 (2022).","journal-title":"PLoS Pathog."},{"key":"38345_CR24","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1056\/NEJMc2209479","volume":"387","author":"J Malato","year":"2022","unstructured":"Malato, J. et al. Risk of BA.5 infection among Persons exposed to previous SARS-CoV-2 variants. N. Engl. J. Med. 387, 953\u2013954 (2022).","journal-title":"N. Engl. J. Med."},{"key":"38345_CR25","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1056\/NEJMc2209371","volume":"387","author":"D-Y Lin","year":"2022","unstructured":"Lin, D.-Y. et al. Effects of vaccination and previous infection on omicron infections in children. N. Engl. J. Med. 387, 1141\u20131143 (2022).","journal-title":"N. Engl. J. Med."},{"key":"38345_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32363-4","volume":"13","author":"H Chemaitelly","year":"2022","unstructured":"Chemaitelly, H. et al. Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage. Nat. Commun. 13, 4675 (2022).","journal-title":"Nat. Commun."},{"key":"38345_CR27","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.cell.2021.12.033","volume":"185","author":"WF Garcia-Beltran","year":"2022","unstructured":"Garcia-Beltran, W. F. et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell 185, 457\u2013466.e4 (2022).","journal-title":"Cell"},{"key":"38345_CR28","doi-asserted-by":"publisher","unstructured":"Alsoussi, W. B. et al. SARS-CoV-2 Omicron boosting induces de novo B cell response in humans. Nature https:\/\/doi.org\/10.1038\/s41586-023-06025-4 (2023).","DOI":"10.1038\/s41586-023-06025-4"},{"key":"38345_CR29","doi-asserted-by":"publisher","first-page":"17957","DOI":"10.1073\/pnas.1906613117","volume":"117","author":"AH Ellebedy","year":"2020","unstructured":"Ellebedy, A. H. et al. Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses in humans. Proc Natl Acad Sci USA 117, 17957\u201317964 (2020).","journal-title":"Proc Natl Acad Sci USA"},{"key":"38345_CR30","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","volume":"584","author":"DF Robbiani","year":"2020","unstructured":"Robbiani, D. F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 584, 437\u2013442 (2020).","journal-title":"Nature"},{"key":"38345_CR31","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","volume":"588","author":"CO Barnes","year":"2020","unstructured":"Barnes, C. O. et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 588, 682\u2013687 (2020).","journal-title":"Nature"},{"key":"38345_CR32","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","volume":"592","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 592, 616\u2013622 (2021).","journal-title":"Nature"},{"key":"38345_CR33","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.coi.2016.06.001","volume":"41","author":"A Lanzavecchia","year":"2016","unstructured":"Lanzavecchia, A., Fr\u00fchwirth, A., Perez, L. & Corti, D. Antibody-guided vaccine design: identification of protective epitopes. Curr. Opin. Immunol. 41, 62\u201367 (2016).","journal-title":"Curr. Opin. Immunol."},{"key":"38345_CR34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.coi.2020.03.013","volume":"65","author":"AB Ward","year":"2020","unstructured":"Ward, A. B. & Wilson, I. A. Innovations in structure-based antigen design and immune monitoring for next generation vaccines. Curr. Opin. Immunol. 65, 50\u201356 (2020).","journal-title":"Curr. Opin. Immunol."},{"key":"38345_CR35","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.immuni.2018.04.029","volume":"48","author":"PD Kwong","year":"2018","unstructured":"Kwong, P. D. & Mascola, J. R. HIV-1 vaccines based on antibody identification, B cell ontogeny, and epitope structure. Immunity 48, 855\u2013871 (2018).","journal-title":"Immunity"},{"key":"38345_CR36","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1126\/science.abc7520","volume":"369","author":"TF Rogers","year":"2020","unstructured":"Rogers, T. F. et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science 369, 956\u2013963 (2020).","journal-title":"Science"},{"key":"38345_CR37","doi-asserted-by":"publisher","first-page":"6675","DOI":"10.1073\/pnas.1921388117","volume":"117","author":"AZ Wec","year":"2020","unstructured":"Wec, A. Z. et al. Longitudinal dynamics of the human B cell response to the yellow fever 17D vaccine. Proc Natl Acad Sci USA 117, 6675\u20136685 (2020).","journal-title":"Proc Natl Acad Sci USA"},{"key":"38345_CR38","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nprot.2007.13","volume":"2","author":"RD Gietz","year":"2007","unstructured":"Gietz, R. D. & Schiestl, R. H. High-efficiency yeast transformation using the LiAc\/SS carrier DNA\/PEG method. Nat. Protoc. 2, 31\u201334 (2007).","journal-title":"Nat. Protoc."},{"key":"38345_CR39","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41586-019-0879-y","volume":"566","author":"B Briney","year":"2019","unstructured":"Briney, B., Inderbitzin, A., Joyce, C. & Burton, D. R. Commonality despite exceptional diversity in the baseline human antibody repertoire. Nature 566, 393\u2013397 (2019).","journal-title":"Nature"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-38345-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-38345-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-38345-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T14:06:44Z","timestamp":1683900404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-38345-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["38345"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-38345-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]},"assertion":[{"value":"9 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.I.K. and L.M.W. are former employees and hold shares in Adimab. LLC. P.K., H.L.D., E.R.C., and J.C.G. are current employees and hold shares in Adimab LLC. L.M.W. is a former employee and holds shares in Invivyd Inc. T.N.S. and J.D.B. consult with Apriori Bio. J.D.B. has consulted for Moderna and Merck on viral evolution and epidemiology. D.R.B. is a consultant for IAVI, Invivyd, Adimab, Mabloc, VosBio, Nonigenex, and Radiant. C.I.K. and L.M.W. are inventors on a provisional patent application (No. 63\/408,980) describing the SARS-CoV-2 antibodies reported in this work. T.N.S. and J.D.B. may receive a share of intellectual property revenue as inventors on Fred Hutchinson Cancer Center\u2013optioned technology and patents related to deep mutational scanning of viral proteins. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2751"}}